17,000 Shares in Nektar Therapeutics $NKTR Bought by Erste Asset Management GmbH

Erste Asset Management GmbH acquired a new stake in Nektar Therapeutics (NASDAQ:NKTR) during the 3rd quarter, Holdings Channel reports. The fund acquired 17,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,002,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Emerald Mutual Fund Advisers Trust acquired a new position in shares of Nektar Therapeutics during the third quarter worth about $13,269,000. Simplify Asset Management Inc. lifted its stake in Nektar Therapeutics by 67.6% in the 3rd quarter. Simplify Asset Management Inc. now owns 87,174 shares of the biopharmaceutical company’s stock valued at $4,960,000 after acquiring an additional 35,176 shares in the last quarter. Emerald Advisers LLC bought a new stake in Nektar Therapeutics in the 3rd quarter valued at approximately $18,393,000. Moody Aldrich Partners LLC boosted its position in Nektar Therapeutics by 62.3% during the 3rd quarter. Moody Aldrich Partners LLC now owns 73,716 shares of the biopharmaceutical company’s stock worth $4,194,000 after acquiring an additional 28,304 shares during the last quarter. Finally, Readystate Asset Management LP bought a new position in shares of Nektar Therapeutics during the 3rd quarter worth approximately $2,563,000. Institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Price Performance

Shares of NKTR opened at $68.98 on Monday. The company has a market cap of $1.40 billion, a PE ratio of -8.66 and a beta of 1.16. The firm has a 50-day moving average of $47.98 and a 200-day moving average of $50.35. Nektar Therapeutics has a one year low of $6.45 and a one year high of $75.67.

Insider Transactions at Nektar Therapeutics

In other Nektar Therapeutics news, insider Jonathan Zalevsky sold 3,867 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $35.67, for a total transaction of $137,935.89. Following the transaction, the insider owned 21,354 shares of the company’s stock, valued at $761,697.18. The trade was a 15.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Howard W. Robin sold 423 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total value of $30,879.00. Following the completion of the sale, the chief executive officer owned 75,489 shares in the company, valued at $5,510,697. This represents a 0.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 4,470 shares of company stock valued at $181,955 in the last quarter. 3.71% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

NKTR has been the topic of a number of research reports. BTIG Research boosted their price objective on shares of Nektar Therapeutics from $118.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. B. Riley Financial reissued a “buy” rating and set a $150.00 price target (up from $105.00) on shares of Nektar Therapeutics in a research report on Monday, February 23rd. HC Wainwright increased their price objective on shares of Nektar Therapeutics from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. Wall Street Zen downgraded Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Nektar Therapeutics in a report on Wednesday, December 17th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $126.29.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.